Condition: Muscle-invasive Bladder Cancer · Sponsor: Spanish Oncology Genito-Urinary Group
Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.
This description comes directly from the study's public registry record.
Isabel Grau · 0034610286915 · trialmanager@sogug.es
Always discuss trial participation with your own doctor first.
| CLCC Jean Perrin | Clermont-Ferrand, France | Recruiting |
| CLCC Léon Bérard | Lyon, France | Withdrawn |
| Institut Mutualiste Montsouris | Paris, France | Recruiting |
| IUCT | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| IRCCS San Raffaele Hospital and Scientific Institute | Milan, Italy | Recruiting |
| A.O. Ordine Mauriziano, Ospedale Umberto I | Turi, Italy | Withdrawn |
| Ospedale Molinette | Turin, Italy | Recruiting |
| Hospital Clínic De Barcelona | Barcelona, Catalonia, Spain | Recruiting |
| Hospital De Sabadell (Parc Taulí) | Barcelona, Catalonia, Spain | Recruiting |
| Complexo Hospitalario Universitario A Coruña | A Coruña, Galicia, Spain | Recruiting |
| Hospital Universitario Lucus Augusti | Lugo, Galicia, Spain | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06511648